Inclusion Criteria:

- Confirmed diagnosis of AML in the status of primary induction failure (i.e.
persistent leukemia after 2 courses of induction chemotherapy or persisting bone
marrow hypoplasia fol-lowing induction chemotherapy +/-minimal residual disease)

- Age: 18-55 years

- Availability of an HLA identical family donor OR unrelated donor with matching in
10/10 alleles (HLA-A, B, C, DRB1, DQB1) or maximum of 1 allele or antigen mismatch OR
family donor with maximum 1 allele mismatch.

- Have adequate renal and hepatic functions as indicated by the following laboratory
values:

- Serum creatinine ≤1.0 mg/dL; if serum creatinine >1.0 mg/dL, then the estimated
glomerular filtration rate (GFR) must be >60 mL/min/1.73 m² as calculated by the
Modification of Diet in Renal Disease equation where Predicted GFR (ml/min/1.73 m2)
= 186 x (Serum Creatinine)-1.154 x (age in years)-0.023 x (0.742 if patient is
female)

- Serum bilirubin ≤1.5 mg/dL × upper limit of normal (ULN)

- Aspartate transaminase (AST)/alanine transaminase (ALT) ≤2.5 × ULN

- Alkaline phosphatase ≤2.5 × ULN

Exclusion Criteria:

- Documented chloroma

- Patients having AML M3

- Documented leukemic infiltration of CNS/cerebrospinal fluid

- Karnofsky performance score below < 60%

- Acute or chronic heart failure

- HIV infection, chronic viral hepatitis

- Severe neurological or psychiatric disorders

- Any circumstances that preclude the use of the drugs used within the protocol

- Prior allogeneic or autologous stem cell transplantation

- > 3 courses of prior chemotherapy

- Denied informed consent

- Pregnancy or denied of effective contraceptive method